The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Communicable Diseases Drugs-Global Market Insights and Sales Trends 2025
Synopsis
In this report, we study the drugs for Communicable Diseases. Communicable diseases are disorders caused by organisms — such as bacteria, viruses,fungi or parasites
The global Communicable Diseases Drugs market size is expected to reach US$ 68580 million by 2029, growing at a CAGR of 6.6% from 2023 to 2029. The market is mainly driven by the significant applications of Communicable Diseases Drugs in various end use industries. The expanding demands from the Hospital, Clinic and Other, are propelling Communicable Diseases Drugs market. HIV, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Influenza segment is estimated at % CAGR for the next seven-year period.
The Communicable Diseases Treatment market refers to the pharmaceuticals and treatments used for the management and control of infectious diseases that can be transmitted from person to person. This market includes antiviral drugs, antibiotics, vaccines, and other therapies. The Communicable Diseases Treatment market has experienced significant growth due to factors such as the increasing prevalence of infectious diseases, the emergence of new pathogens, and the need for effective treatment options. Key players in the market include pharmaceutical companies, biotechnology firms, and government healthcare agencies. Geographically, the market is diverse, with regions facing different communicable disease burdens.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Communicable Diseases Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Communicable Diseases Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Communicable Diseases Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Communicable Diseases Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Communicable Diseases Drugs covered in this report include Novartis, Gilead, GSK, Roche, Merck, Boehringer Ingelheim, Eli Lilly, AstraZeneca and J & J, etc.
The global Communicable Diseases Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Gilead
GSK
Roche
Merck
Boehringer Ingelheim
Eli Lilly
AstraZeneca
J & J
Teva
AbbVie
Bausch Health
Abbott
Sanofi
Sun Pharma
Endo
Apotex
Amneal Pharma
Torrent Pharma
Global Communicable Diseases Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Communicable Diseases Drugs market, Segment by Type:
HIV
Influenza
TB
Malaria
Hepatitis
HPV
Global Communicable Diseases Drugs market, by Application
Hospital
Clinic
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Communicable Diseases Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
In this report, we study the drugs for Communicable Diseases. Communicable diseases are disorders caused by organisms — such as bacteria, viruses,fungi or parasites
The global Communicable Diseases Drugs market size is expected to reach US$ 68580 million by 2029, growing at a CAGR of 6.6% from 2023 to 2029. The market is mainly driven by the significant applications of Communicable Diseases Drugs in various end use industries. The expanding demands from the Hospital, Clinic and Other, are propelling Communicable Diseases Drugs market. HIV, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Influenza segment is estimated at % CAGR for the next seven-year period.
The Communicable Diseases Treatment market refers to the pharmaceuticals and treatments used for the management and control of infectious diseases that can be transmitted from person to person. This market includes antiviral drugs, antibiotics, vaccines, and other therapies. The Communicable Diseases Treatment market has experienced significant growth due to factors such as the increasing prevalence of infectious diseases, the emergence of new pathogens, and the need for effective treatment options. Key players in the market include pharmaceutical companies, biotechnology firms, and government healthcare agencies. Geographically, the market is diverse, with regions facing different communicable disease burdens.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Communicable Diseases Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Communicable Diseases Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Communicable Diseases Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Communicable Diseases Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Communicable Diseases Drugs covered in this report include Novartis, Gilead, GSK, Roche, Merck, Boehringer Ingelheim, Eli Lilly, AstraZeneca and J & J, etc.
The global Communicable Diseases Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Gilead
GSK
Roche
Merck
Boehringer Ingelheim
Eli Lilly
AstraZeneca
J & J
Teva
AbbVie
Bausch Health
Abbott
Sanofi
Sun Pharma
Endo
Apotex
Amneal Pharma
Torrent Pharma
Global Communicable Diseases Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Communicable Diseases Drugs market, Segment by Type:
HIV
Influenza
TB
Malaria
Hepatitis
HPV
Global Communicable Diseases Drugs market, by Application
Hospital
Clinic
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Communicable Diseases Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Communicable Diseases Drugs
1.1 Communicable Diseases Drugs Market Overview
1.1.1 Communicable Diseases Drugs Product Scope
1.1.2 Communicable Diseases Drugs Market Status and Outlook
1.2 Global Communicable Diseases Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Communicable Diseases Drugs Market Size by Region (2018-2029)
1.4 Global Communicable Diseases Drugs Historic Market Size by Region (2018-2023)
1.5 Global Communicable Diseases Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Communicable Diseases Drugs Market Size (2018-2029)
1.6.1 North America Communicable Diseases Drugs Market Size (2018-2029)
1.6.2 Europe Communicable Diseases Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Communicable Diseases Drugs Market Size (2018-2029)
1.6.4 Latin America Communicable Diseases Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Communicable Diseases Drugs Market Size (2018-2029)
2 Communicable Diseases Drugs Market by Type
2.1 Introduction
2.1.1 HIV
2.1.2 Influenza
2.1.3 TB
2.1.4 Malaria
2.1.5 Hepatitis
2.1.6 HPV
2.2 Global Communicable Diseases Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Communicable Diseases Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Communicable Diseases Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Communicable Diseases Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Communicable Diseases Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Communicable Diseases Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Communicable Diseases Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Communicable Diseases Drugs Revenue Breakdown by Type (2018-2029)
3 Communicable Diseases Drugs Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinic
3.1.3 Other
3.2 Global Communicable Diseases Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Communicable Diseases Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Communicable Diseases Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Communicable Diseases Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Communicable Diseases Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Communicable Diseases Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Communicable Diseases Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Communicable Diseases Drugs Revenue Breakdown by Application (2018-2029)
4 Communicable Diseases Drugs Competition Analysis by Players
4.1 Global Communicable Diseases Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Communicable Diseases Drugs as of 2022)
4.3 Date of Key Players Enter into Communicable Diseases Drugs Market
4.4 Global Top Players Communicable Diseases Drugs Headquarters and Area Served
4.5 Key Players Communicable Diseases Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Communicable Diseases Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Novartis
5.1.1 Novartis Profile
5.1.2 Novartis Main Business
5.1.3 Novartis Communicable Diseases Drugs Products, Services and Solutions
5.1.4 Novartis Communicable Diseases Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Novartis Recent Developments
5.2 Gilead
5.2.1 Gilead Profile
5.2.2 Gilead Main Business
5.2.3 Gilead Communicable Diseases Drugs Products, Services and Solutions
5.2.4 Gilead Communicable Diseases Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Gilead Recent Developments
5.3 GSK
5.3.1 GSK Profile
5.3.2 GSK Main Business
5.3.3 GSK Communicable Diseases Drugs Products, Services and Solutions
5.3.4 GSK Communicable Diseases Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Roche Recent Developments
5.4 Roche
5.4.1 Roche Profile
5.4.2 Roche Main Business
5.4.3 Roche Communicable Diseases Drugs Products, Services and Solutions
5.4.4 Roche Communicable Diseases Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Roche Recent Developments
5.5 Merck
5.5.1 Merck Profile
5.5.2 Merck Main Business
5.5.3 Merck Communicable Diseases Drugs Products, Services and Solutions
5.5.4 Merck Communicable Diseases Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Merck Recent Developments
5.6 Boehringer Ingelheim
5.6.1 Boehringer Ingelheim Profile
5.6.2 Boehringer Ingelheim Main Business
5.6.3 Boehringer Ingelheim Communicable Diseases Drugs Products, Services and Solutions
5.6.4 Boehringer Ingelheim Communicable Diseases Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Boehringer Ingelheim Recent Developments
5.7 Eli Lilly
5.7.1 Eli Lilly Profile
5.7.2 Eli Lilly Main Business
5.7.3 Eli Lilly Communicable Diseases Drugs Products, Services and Solutions
5.7.4 Eli Lilly Communicable Diseases Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Eli Lilly Recent Developments
5.8 AstraZeneca
5.8.1 AstraZeneca Profile
5.8.2 AstraZeneca Main Business
5.8.3 AstraZeneca Communicable Diseases Drugs Products, Services and Solutions
5.8.4 AstraZeneca Communicable Diseases Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 AstraZeneca Recent Developments
5.9 J & J
5.9.1 J & J Profile
5.9.2 J & J Main Business
5.9.3 J & J Communicable Diseases Drugs Products, Services and Solutions
5.9.4 J & J Communicable Diseases Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 J & J Recent Developments
5.10 Teva
5.10.1 Teva Profile
5.10.2 Teva Main Business
5.10.3 Teva Communicable Diseases Drugs Products, Services and Solutions
5.10.4 Teva Communicable Diseases Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 Teva Recent Developments
5.11 AbbVie
5.11.1 AbbVie Profile
5.11.2 AbbVie Main Business
5.11.3 AbbVie Communicable Diseases Drugs Products, Services and Solutions
5.11.4 AbbVie Communicable Diseases Drugs Revenue (US$ Million) & (2018-2023)
5.11.5 AbbVie Recent Developments
5.12 Bausch Health
5.12.1 Bausch Health Profile
5.12.2 Bausch Health Main Business
5.12.3 Bausch Health Communicable Diseases Drugs Products, Services and Solutions
5.12.4 Bausch Health Communicable Diseases Drugs Revenue (US$ Million) & (2018-2023)
5.12.5 Bausch Health Recent Developments
5.13 Abbott
5.13.1 Abbott Profile
5.13.2 Abbott Main Business
5.13.3 Abbott Communicable Diseases Drugs Products, Services and Solutions
5.13.4 Abbott Communicable Diseases Drugs Revenue (US$ Million) & (2018-2023)
5.13.5 Abbott Recent Developments
5.14 Sanofi
5.14.1 Sanofi Profile
5.14.2 Sanofi Main Business
5.14.3 Sanofi Communicable Diseases Drugs Products, Services and Solutions
5.14.4 Sanofi Communicable Diseases Drugs Revenue (US$ Million) & (2018-2023)
5.14.5 Sanofi Recent Developments
5.15 Sun Pharma
5.15.1 Sun Pharma Profile
5.15.2 Sun Pharma Main Business
5.15.3 Sun Pharma Communicable Diseases Drugs Products, Services and Solutions
5.15.4 Sun Pharma Communicable Diseases Drugs Revenue (US$ Million) & (2018-2023)
5.15.5 Sun Pharma Recent Developments
5.16 Endo
5.16.1 Endo Profile
5.16.2 Endo Main Business
5.16.3 Endo Communicable Diseases Drugs Products, Services and Solutions
5.16.4 Endo Communicable Diseases Drugs Revenue (US$ Million) & (2018-2023)
5.16.5 Endo Recent Developments
5.17 Apotex
5.17.1 Apotex Profile
5.17.2 Apotex Main Business
5.17.3 Apotex Communicable Diseases Drugs Products, Services and Solutions
5.17.4 Apotex Communicable Diseases Drugs Revenue (US$ Million) & (2018-2023)
5.17.5 Apotex Recent Developments
5.18 Amneal Pharma
5.18.1 Amneal Pharma Profile
5.18.2 Amneal Pharma Main Business
5.18.3 Amneal Pharma Communicable Diseases Drugs Products, Services and Solutions
5.18.4 Amneal Pharma Communicable Diseases Drugs Revenue (US$ Million) & (2018-2023)
5.18.5 Amneal Pharma Recent Developments
5.19 Torrent Pharma
5.19.1 Torrent Pharma Profile
5.19.2 Torrent Pharma Main Business
5.19.3 Torrent Pharma Communicable Diseases Drugs Products, Services and Solutions
5.19.4 Torrent Pharma Communicable Diseases Drugs Revenue (US$ Million) & (2018-2023)
5.19.5 Torrent Pharma Recent Developments
6 North America
6.1 North America Communicable Diseases Drugs Market Size by Country (2018-2029)
6.2 the United States
6.3 Canada
7 Europe
7.1 Europe Communicable Diseases Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Communicable Diseases Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Communicable Diseases Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Communicable Diseases Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Communicable Diseases Drugs Market Dynamics
11.1 Communicable Diseases Drugs Industry Trends
11.2 Communicable Diseases Drugs Market Drivers
11.3 Communicable Diseases Drugs Market Challenges
11.4 Communicable Diseases Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
